Trials / Unknown
UnknownNCT00631501
Doxycycline for Lateral Epicondylalgia - RCT
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 34 (estimated)
- Sponsor
- Kaunas University of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Matrix metalloproteinases are involved in the pathogenesis of tendinopathy. Doxycycline, a widely available pharmaceutical agent mostly used for its antibiotic properties, also functions as an inhibitor of MMPs. This study aims to investigate the effect of doxycycline treatment on lateral epicondylalgia (tennis elbow). During three weeks, patients receive doxycycline tablets 100 mg twice daily, or placebo. Main outcome variable is pain (VAS) at three weeks. Serum and/or plasma levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases are measured.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | |
| DRUG | Doxycycline |
Timeline
- First posted
- 2008-03-07
- Last updated
- 2008-03-07
Locations
1 site across 1 country: Lithuania
Source: ClinicalTrials.gov record NCT00631501. Inclusion in this directory is not an endorsement.